property Rights


That any pharma product has successfully undergo the regulatory affairs scanners before launched within the market need less to say . Biosimilars and biologics are not any exceptions. the businesses developing these biosimilars and biologics aside from regulatory aspects tend to enjoy monopoly over their product. property Rights (IPR) and patents are ultimate tools to the biosimilar manufacturers for safeguarding their interests. 2016 was a record year for development of Biosimilars & biologics in US. during this year 16 IPR petition was filed. So, expected scenario of 2017 would be a boom in Biosimilar and biologics field.


  • The Budapest Treaty
  • The Patent Act and biological innovations
  • TRIPS negotiations on biotechnology

Related Conference of property Rights

December 05-06, 2023

2nd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
February 01-02, 2024

37th World Congress on Pharmacology

Dubai, UAE
February 22-23, 2024

34th Annual European Pharma Congress

Zurich, Switzerland
April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France

property Rights Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in